Session Description:

Innovation of technology in type 1 diabetes has transformed the therapy and significantly improved both clinical and patient related outcomes. This symposium, chaired by Prof. Chantal Mathieu, will focus on extending the use of the MiniMed™ 780G system to the wider population of people with type 1 diabetes, in terms of clinical outcomes, patient related outcomes, and economic value. The results of three studies evaluating the MiniMed™ 780G system will be presented for the first time: Prof. Pratik Choudhary will discuss the transition of people not achieving the treatment goals with MDI and isCGM, followed by Prof. Tomasz Klupa who will address the transition of those totally naïve to pump or CGM technologies. The use of the MiniMed™ 780G system with Fiasp in the adolescent population during exercise, will be further discussed by Dr. Klemen Dovc.

Lastly, Prof. Ohad Cohen, Medical Director of Medtronic, will summarize the data presented and its implications on successfully achieving goals in growing populations and indications of people with type 1 diabetes.